216 related articles for article (PubMed ID: 32962737)
21. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.
Deibener J; Kaminsky P; Jacob C; Dousset B; Klein M; Duc M
Haematologica; 1998 May; 83(5):479-80. PubMed ID: 9658738
[TBL] [Abstract][Full Text] [Related]
22. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
[TBL] [Abstract][Full Text] [Related]
24. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?
Andrade-Campos M; Escuder-Azuara B; de Frutos LL; Serrano-Gonzalo I; Giraldo P; ; ;
Blood Cells Mol Dis; 2020 Nov; 85():102478. PubMed ID: 32688219
[TBL] [Abstract][Full Text] [Related]
25. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
26. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
27. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
28. Gaucher's disease in Lithuania: its diagnosis and treatment.
Kleinotienė G; Tylki-Szymanska A; Czartoryska B
Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
[TBL] [Abstract][Full Text] [Related]
29. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
[TBL] [Abstract][Full Text] [Related]
30. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
[TBL] [Abstract][Full Text] [Related]
31. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy.
Mistry PK; Sirrs S; Chan A; Pritzker MR; Duffy TP; Grace ME; Meeker DP; Goldman ME
Mol Genet Metab; 2002; 77(1-2):91-8. PubMed ID: 12359135
[TBL] [Abstract][Full Text] [Related]
33. [Gaucher's disease with D409H/D409H genotype. evolution with enzyme replacement therapy].
Castelló Girona F; Domínguez Luengo C; del Toro Riera M; Chabás Bergon A
An Esp Pediatr; 2001 Mar; 54(3):310-2. PubMed ID: 11262263
[TBL] [Abstract][Full Text] [Related]
34. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
MacKenzie JJ; Amato D; Clarke JT
CMAJ; 1998 Nov; 159(10):1273-8. PubMed ID: 9861225
[TBL] [Abstract][Full Text] [Related]
35. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
36. Initiation of enzyme replacement therapy for an adult patient with asymptomatic type 1 Gaucher's disease.
Tanaka N; Saito H; Ito T; Momose K; Ishida F; Hora K; Kiyosawa K; Ida H
Intern Med; 2001 Aug; 40(8):716-21. PubMed ID: 11518109
[TBL] [Abstract][Full Text] [Related]
37. Effect of treatment on biclonal gammopathy associated with Gaucher disease.
Decaux O; Ruelland A; Grosbois B
J Inherit Metab Dis; 2007 Oct; 30(5):824. PubMed ID: 17879146
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
39. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
[TBL] [Abstract][Full Text] [Related]
40. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
Latre P; Giraldo P
Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
